65308NPI

A specialty pharmaceutical company focused on developing and commercializing therapies for central nervous system disorders, including treatments for epilepsy and psychiatric conditions. Its pipeline includes both branded and generic products, with a recent emphasis on abuse-deterrent formulations. Investors track it for its niche CNS portfolio and regulatory milestones.